CYRX - Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
(NewsDirect)
By David Willey, Benzinga
Cryoport Inc. (NASDAQ: CYRX) provides the life sciences industry withcomprehensive supply chain solutions to support vital therapeutics. Byoffering a platform of end-to-end, fast and technologically advancedpackaging and logistics services, Cryoport has filled a key needsupporting cell and gene therapies.
In the biotech industry, the cell and gene therapy(CGT) market in particular has seen significant growth and has ampleroom to expand further given longer life expectancies and increasingdemand for personalized medicine. Currently worth $18.61 billion, it has been forecasted by Precedence Research to growat a compound annual growth rate (CAGR) of 22.41% to over $93 billionby 2030. This is in response to massive investment and innovation inthe market that has seen 20 Food and Drug Administration (FDA)-approved CGT treatments in thepast two decades. Many promising CGT start-ups have entered themarket, with the top 50 drawing over $11 billion in funding in thepast few years.
Leading biotech and pharmaceutical companies that are alreadyactive in the CGT space include Allogene Therapeutics (NASDAQ:ALLO), Gilead (NASDAQ: GILD), and Novartis (NYSE:NVS).
An example of innovation in theCGT space is Chimeric antigen receptor (CAR) T-cell therapy forcancer, a cell therapy that repurposes the immune system to fightcancer without the toxic side effects of treatments like chemotherapy.CAR-T therapy has shown amazing complete remission rates, with onestudy showing completeremission in 99% of children with acute lymphocytic leukemia(ALL) in a clinical trial, with 74% showing no signs or symptoms ofthe disease after a full year. For adults, CAR-T also has high earlyremission rates of 81%.
Cryoport’s Pivotal Placement In theIndustry
Allthese companies developing innovative treatments in the CGT space needa comprehensive infrastructure to support the advancement of thesecritical patient therapeutics. Cryoport, an integrated cold-chainsupply chain and logistics company, provides these companies with theessential support they need to provide these life-saving therapies.
One of thelargest temperature-controlled supply chain companies, Cryoport hasbuilt up a client base of over 3,000 customers worldwide and deliveredmore than a million shipments. It is actively involved in over 650clinical trials, making it a lynchpin at the heart of the dynamic CGTindustry as it develops. According to an investment report by BTIG, in2021 alone 21 groups supported by Cryoport filed market authorizationapplications (MAA) or biologic license applications (BLA).
Cryoport’scomprehensive, turn-key solutions cover a wide range of activities. Ithas four principal divisions: its logistical packaging solutions(Cryoport Systems), a specialty courier service (CYROPDP), itsbiostorage capabilities (Cryogene), and cryogenic systemsmanufacturing (MVE). Cryoport’s end-to-end service engagement makesthe company a must-have facilitator for the developing industry.
One of the winners of theCold Chain Global Forum Excellence Awards, and with 48 facilities in17 countries, the company has made a series of strategic partnershipsand acquisitions to consolidate its position. In 2020, it acquired MVE Biological Solutions (MVE), a global leader in manufacturingvacuum sealed and cryogenic freezer systems. This acquisitionreinforced the Cryoport ecosystem, empowering the company with greatercontrol over the entire process. More recently, through partnershipsand acquisitions with Belgium and French life sciences companies, Cryoport has strengthened its internationalnetwork and further integrated its operations.
A strong base ofindustry relationships, an integrated network and technology, and aglobal system with leading compliance and efficiency, all makeCryoport a sticky and necessary solution for CGT companies. As the CGTindustry continues to grow, Cryoport intends to grow its network toserve these companies.
“The fundamental technology that we have is vital to the lifesciences and its advancement,” said Jerrell Shelton, CEO of Cryoport, commenting on the opening of a newfacility in Texas. “The growth [of the industry] is rapid – butthe supporting infrastructure isn’t.” He went on to explain howCryoport, which represents 90% of commercial CGT therapies currentlyon the market, services the rapidly increasing number of therapydevelopers. “They need reliable partners, with suitable facilitiesto help them manage their valuable materials – including thetherapeutic materials and the raw materials that are used in themanufacturing process.” This is the pivotal role that Cryoport playsin the industry.
Cryoport is heavily owned by institutional investors including Blackstone (BX: NYSE), and now more retail investors seem to bediscovering the necessary role this company plays in the industry.While there are often opportunities to invest in individual biotechcompanies with upcoming catalysts, Cryoport’s diverse biotechcustomer base means an investor gets secondary access to a whole rangeof biomedical companies at different stages of bringing their productsto market — possibly offering a uniquely diversified exposure to theupside of biotech. In fact, there are 11 new Cryoport supportedproducts expected to reach commercialization in 2023, bringing thetotal number of commercialized Cryoport supported therapies to21.
Want to learnmore about what Cryoport is doing in the life sciences industry? Visit its website .
This article was originally published onBenzinga here .
Cryoport,Inc. (Nasdaq: CYRX), is a global leader in temperature-controlledsupply chain solutions for the life sciences industry supportinglife-saving cell and gene therapies across the research, clinical andcommercial spectrum. With over 40 strategic locations covering theAmericas, EMEA (Europe, the Middle East and Africa) and APAC (AsiaPacific), Cryoport's global platform provides mission-criticalsolutions, services, and products to the biopharma/pharma, animalhealth, and reproductive medicine markets worldwide. In addition toits standard setting supply chain solutions, Cryoport is theworld's largest manufacturer of cryogenic systems and one of thelargest life science focused specialtycouriers.
Statements in this press release which are notpurely historical, including statements regarding the Company'sintentions, hopes, beliefs, expectations, representations,projections, plans or predictions of the future, are forward-lookingstatements within the meaning of the Private Securities LitigationReform Act of 1995. These forward-looking statements include, but arenot limited to, those related to the Company's industry, business,plans, strategy, acquisitions, financial results and financialcondition. It is important to note that the Company's actualresults could differ materially from those in any such forward-lookingstatements. Factors that could cause actual results to differmaterially include, but are not limited to, risks and uncertaintiesassociated with the effect of changing economic conditions, trends inthe products markets, variations in the Company's cash flow,market acceptance risks, and technical development risks. TheCompany's business could be affected by a number of other factors,including the risk factors discussed in the Company's Securitiesand Exchange Commission ("SEC") reports including, but notlimited to, the Company's Annual Report on Form 10-K for the threeand twelve months ended December 31, 2022 and any subsequent filingswith the SEC. The forward-looking statements contained in this pressrelease speak only as of the date hereof and the Company cautionsinvestors not to place undue reliance on these forward-lookingstatements. Except as required by law, the Company disclaims anyobligation, and does not undertake to update or revise anyforward-looking statements in this press release.
Thispost contains sponsored advertising content. This content is forinformational purposes only and is not intended to be investingadvice.
Contact Details
Todd Fromer- KCSAStrategic Communications
CompanyWebsite
Copyright (c) 2023 TheNewswire - All rights reserved.